<DOC>
	<DOCNO>NCT00098098</DOCNO>
	<brief_summary>The purpose trial evaluate safety tolerability two-dose regimen ( Day 0 Day 28 ) recombinant Botulinum Vaccine ( rBV ) A/B healthy volunteer give intramuscularly three ascend dosage level cohort two-dose regimen ( Day 0 Day 28 ) formulation contain antigen 40 ug total immunizing protein dosage level .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability Immunogenicity Recombinant Botulinum Vaccine A/B Healthy Adults</brief_title>
	<detailed_description>The Phase 1 clinical trial design single-center , open-label , non-randomized study evaluate safety , tolerability immunogenicity two-dose schedule rBV A/B healthy volunteer three ascend dosage level , 5 ug , 10 ug 20 ug serotype-specific antigen ( 10 ug , 20 ug 40 ug total immunize protein ) three dose cohort two-dose regimen ( Day 0 Day 28 ) formulation contain antigen 40 ug total immunizing protein dosage level . Approximately 44 volunteer ( 11 per cohort ) expect enrolled . Cohorts enroll consecutively begin low dosage level . Volunteers cohort receive two injection series assign dosage level give 0.5 mL intramuscular ( i.m . ) injection Day 0 Day 28 . Potential volunteer study participation undergo qualification screen study 21 day prior date schedule vaccination . After successful completion inform consent process screen assessment , volunteer schedule vaccination . Volunteers report acute adverse event daily 28 day vaccination return clinic regular interval accord Schedule Study Assessments last schedule follow-up 168 day ( ± 7 day ) initial vaccination ( Day 0 ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria The volunteer 18 40 ( inclusive ) year age time first dose rBV A/B . The volunteer good health determine Investigator ( Study Doctor ) medical history physical examination . The volunteer clinical chemistry , hematology urinalysis laboratory value within 10 % upper within 10 % low limit normal range establish University Kentucky clinical laboratory consider clinically significant Investigator and/or Sponsor Medical Monitor . The volunteer normal electrocardiogram ( ECG ) . However , potential volunteer report benign ECG abnormality ( e.g. , sinus bradycardia ) result may discuss Sponsor Medical Monitor . With agreement Sponsor Medical Monitor documentation consultation volunteer 's study record , Investigator may include volunteer study . The volunteer willing blood sample store future botulinum research study . The volunteer sign Informed Consent Form , successfully complete ( least 90 % correct ) Test Understanding , sign Health Insurance Portability Accountability Act ( HIPAA ) authorization form . The volunteer agree donate blood least 30 day follow vaccination . The volunteer willing comply requirement protocol postvaccination Day 168 ( ± 7 day ) visit . Female volunteer must nonchildbearing potential ( i.e. , surgically sterilize postmenopausal ) , must pregnant ( indicated negative serum pregnancy test within 24 hour prior rBV A/B administration ) nursing , must use two type acceptable form FDAapproved birth control method include : 1 ) hormonal type birth control ( implant birth control pill ) intrauterine device ( IUD ) 2 ) additional barrier type birth control measure ( i.e . condom , diaphragm , cervical cap , spermicide , etc . ) period begin 30 day vaccination completion study . Completion study define complete postvaccination Day 168 ( ± 7 day ) visit . Exclusion Criteria The volunteer frequent severe headache etiology . The volunteer chronic , severe recurrent joint pain arthritis etiology . The volunteer history alcohol drug abuse within 12 month prior study screen history injectable drug use . The volunteer positive result urine drug screen test common substance abuse amphetamine , barbiturate , benzodiazepine , cocaine , opiates , cannabinoids . ( If positive screen , confirmatory test shall perform applicable ) . The volunteer previous diagnosis serious psychiatric disorder . For purpose , serious psychiatric disorder define illness require hospitalization within previous 12 month ; routine administration one medication control anxiety , mood sleep disorder ; history suicide attempt . The volunteer receive blood product immune globulin previous six month . The volunteer donate blood within past 56 day . The volunteer receive investigational drug therapy within 30 day first dose rBV A/B intend receive investigational drug therapy postvaccination Day 168 ( ± 7 day ) visit . Licensed vaccine exclusionary give least 30 day immunization ( live vaccine : 60 day immunization ) avoid potential confusion adverse reaction . The volunteer receive investigational Botulinum Vaccine Toxoid . The volunteer receive previous treatment approve therapeutic product contain botulinum neurotoxin Botox , Myobloc , Botox Cosmetic . The volunteer clinically significant abnormality ECG . The volunteer know hypersensitivity aluminum compound yeast . The volunteer laboratory value great 10 % upper great 10 % low limit normal clinically significant assessed Investigator and/or Sponsor Medical Monitor . The volunteer test positive Human Immunodeficiency Virus ( HIV ) ; Hepatitis C Virus ( HCV ) Hepatitis B surface Antigen ( HBsAg ) . The volunteer body mass index &gt; 40 kg/m2 &gt; 100 lb . ideal body weight . The volunteer acute illness , evidence significant active infection , evidence systemic disease time enrollment opinion Investigator would place volunteer unacceptable risk injury . The volunteer temperature &gt; 100.4 °F time enrollment . The volunteer occupational responsibility would prevent completion participation study . The volunteer history anaphylaxis serious adverse reaction vaccine . The volunteer personal family history multiple sclerosis . The female volunteer pregnant ( must negative serum pregnancy test within 24 hour prior dose rBV A/B ) , lactate unwilling use two type acceptable form FDAapproved contraception 30 day prior first dose rBV A/B postvaccination Day 168 ( ± 7 day ) visit . The volunteer require chemotherapeutic immunosuppressive agent total corticosteroid dose 2 mg/kg 20 mg/day within 3 month prior study burst steroid therapy within 14 day vaccination . The volunteer currently active duty US military . The volunteer US military veteran receive botulinum product vaccination research purpose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Botulinum</keyword>
	<keyword>Recombinant Botulinum Vaccine</keyword>
	<keyword>botulinum neurotoxin</keyword>
</DOC>